https://scholars.lib.ntu.edu.tw/handle/123456789/520054
標題: | Antihypertensive agents and risk of Parkinson's disease: A nationwide cohort study | 作者: | Lee Y.-C. CHIN-HSIEN LIN RUEY-MEEI WU JOU-WEI LIN CHIA-HSUIN CHANG Lai M.-S. |
公開日期: | 2014 | 出版社: | Public Library of Science | 卷: | 9 | 期: | 6 | 來源出版物: | PLoS ONE | 摘要: | Background and Purpose: Hypertension has been associated with Parkinson's disease (PD), but data on antihypertensive drugs and PD are inconclusive. We aim to evaluate antihypertensive drugs for an association with PD in hypertensive patients. Methods: Hypertensive patients who were free of PD, dementia and stroke were recruited from 2005-2006 using Taiwan National Health Insurance Database. We examined the association between the use of calcium channel blockers (CCBs), angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs) and the incidence of PD using beta-blockers as the reference. Cox regression model with time-varying medication use was applied. Results: Among 65,001 hypertensive patients with a mean follow-up period of 4.6 years, use of dihydropyridine CCBs, but not non-dihydropyridine CCBs, was associated with a reduced risk of PD (adjusted hazard ratio [aHR] = 0.71; 95% CI, 0.57-0.90). Additionally, use of central-acting CCBs, rather than peripheral-acting ones, was associated with a decreased risk of PD (aHR = .69 [55-0.87]. Further decreased association was observed for higher cumulative doses of felodipine (aHR = 0.54 [0.36-0.80]) and amlodipine (aHR = 0.60 [0.45-0.79]). There was no association between the use of ACEIs (aHR = 0.80 [0.64-1.00]) or ARBs (aHR = 0.86 [0.69-1.08]) with PD. A potentially decreased association was only found for higher cumulative use of ACEIs (HR = 0.52 [0.34-0.80]) and ARBs (HR = 0.52 [0.33-0.80]). Conclusions: Our study suggests centrally-acting dihydropyridine CCB use and high cumulative doses of ACEIs and ARBs may associate with a decreased incidence of PD in hypertensive patients. Further long-term follow-up studies are needed to confirm the potential beneficial effects of antihypertensive agents in PD. ? 2014 Lee et al. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84902584567&doi=10.1371%2fjournal.pone.0098961&partnerID=40&md5=5e739ff48aab0e896c7e874231b47843 https://scholars.lib.ntu.edu.tw/handle/123456789/520054 |
ISSN: | 1932-6203 | DOI: | 10.1371/journal.pone.0098961 | SDG/關鍵字: | amlodipine; angiotensin receptor antagonist; calcium channel blocking agent; diltiazem; dipeptidyl carboxypeptidase inhibitor; felodipine; lacidipine; lercanidipine; nifedipine; nitrendipine; verapamil; angiotensin receptor antagonist; antihypertensive agent; calcium channel blocking agent; dipeptidyl carboxypeptidase inhibitor; adult; aged; article; cohort analysis; controlled study; disease association; dose response; female; high risk patient; human; hypertension; incidence; major clinical study; male; Parkinson disease; risk assessment; risk reduction; Parkinson disease; proportional hazards model; risk; Taiwan; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Cohort Studies; Female; Humans; Male; Parkinson Disease; Proportional Hazards Models; Risk; Taiwan |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。